Handbook of Contemporary Neuropharmacology, 3 Volume Set

1. Auflage 2007
ISBN: 978-0-471-66053-8
Verlag: Wiley

Buch, Englisch, 2992 Seiten, Format (B × H): 210 mm x 275 mm, Gewicht: 5852 g

A comprehensive, accessible reference for neuropharmacology

Recognizing the central role of neuropharmacology in drug development, therapy, and the potential for developing novel classes of neuropharmacologic agents stemming from current research, prominent experts collaborated to develop this comprehensive, up-to-date reference that consolidates information about the latest approaches and advances in neuropharmacology in general, and in the research and treatment of specific conditions. Edited by leaders in neuropharmacology and featuring chapters by respected authorities in their specialty areas, Handbook of Contemporary Neuropharmacology is an invaluable resource for pharmacologists, neurologists, psychiatrists, pharmaceutical professionals, and students. It covers basic neuropharmacology and then delves into its applications in research and in treating specific disorders:

* Mood Disorders
* Anxiety and Stress Disorders
* Schizophrenia and Psychosis
* Substance Abuse and Addictive Disorders
* Pain
* Sleep and Arousal
* Development and Developmental Disorders
* Neurodegenerative and Seizure Disorders
* Neuroimmunology
* Eating and Metabolic Disorders

Autoren/Hrsg.

Sibley, David R.

Hanin, Israel

Kuhar, Michael

Skolnick, Phil

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft

Inhaltsverzeichnis

Preface.

Contributors.

VOLUME 1.

PART I: BASIC NEUROPHARMACOLOGY.

PART II: MOOD DISORDERS.

VOLUME 2.

PART I: ANXIETY AND STRESS DISORDERS.

PART II: SCHIZOPHRENIA AND PSYCHOSIS.

PART III: SUBSTANCE ABUSE AND ADDICTIVE DISORDERS.

PART IV: PAIN.

VOLUME 3.

PART I: SLEEP AND AROUSAL.

PART II: DEVELOPMENT AND DEVELOPMENTAL DISORDERS.

PART III: NEURODEGENERATIVE AND SEIZURE DISORDERS.

PART IV: NEUROIMMUNOLOGY.

PART V: EATING AND METABOLIC DISORDERS.

Cumulative Index.

Über Autor(innen)

DAVID R. SIBLEY, PhD, is a Senior Investigator and Chief of the Molecular Neuropharmacology Section in the National Institute of Neurological Disorders and Stroke, National Institutes of Health. His laboratory is currently investigating the molecular, cellular, and biochemical properties of dopamine receptors and their role in neuronal signaling and pathophysiological states.

ISRAEL HANIN, PhD, is Professor and Chair Emeritus in the Department of Pharmacology at Loyola University Chicago. He formerly worked at the National Institute of Mental Health, Laboratory of Preclinical Pharmacology, and at the University of Pittsburgh Department of Psychiatry. Dr. Hanin's research has focused on cholinergic mechanisms, animal models for Alzheimer's disease, and the potential role of glycosaminoglycans in the treatment of Alzheimer's disease.

MICHAEL KUHAR, PhD, is currently a Candler Professor and Georgia Research Alliance Professor of Neuropharmacology at the Yerkes Primate Center at Emory University. He previously was a professor in the Neuroscience Department at Johns Hopkins, and a branch chief at the National Institute on Drug Abuse. Dr. Kuhar has published more than 800 articles, abstracts, book chapters, reviews, and patents.

PHIL SKOLNICK, PhD, D.Sc. (hon.), is Executive Vice President and Chief Scientific Officer for DOV Pharmaceutical, Inc. He was formerly a Lilly Fellow in Neuroscience and also served as Chief of the Laboratory of Neuroscience, National Institutes of Health.